EVERSANA and Waltz Health merge to form new pharma commercialization and drug access platform

EVERSANA and Waltz Health have merged to create a combined platform that integrates commercialization services with payer technology, with the aim of addressing patient access, affordability, and drug value in the US healthcare system. 

The merger brings together EVERSANA’s global commercialization infrastructure with Waltz Health’s software-driven platforms, creating a single organization positioned to work across the full chain of pharmaceutical access. The companies said the integration will allow life sciences firms to connect more directly with payers and patients through technology-enabled solutions. 

Mark Thierer, Co-founder and CEO of Waltz Health and Chairman of EVERSANA, has been appointed CEO. Jim Lang, EVERSANA’s former CEO, will remain on the board. 

“By combining EVERSANA’s pharma services with Waltz’s technology-enabled payer solutions, we’re creating a unified platform that connects life sciences innovation directly to the organizations and individuals we’re meant to serve,” Thierer said.  

Combining commercialization and payer technology 

EVERSANA provides services for pharmaceutical and biotechnology companies including product launches, reimbursement support, patient engagement, and real-world evidence (RWE). Waltz Health adds drug-price marketplaces, AI-enabled prescription routing, and affordability tools connected with insurers, self-insured employers, government programs, and pharmacy benefit managers (PBMs). 

It is hoped that the merger will be particularly impactful in lowering the cost of specialty medicines and high-cost drug classes, such as GLP-1 therapies, by leveraging the combined company's expertise and experience. 

According to the companies, the merger will extend EVERSANA’s services in four areas: commercialization infrastructure; direct-to-payer and patient connectivity; affordability and adherence solutions such as copay optimization and pharmacy routing; and an expanded specialty pharmacy network through Waltz Connect. 

Industry context 

The merger comes as drug pricing and affordability remain central issues in US healthcare. The combined platform is described as an approach intended to improve transparency, reduce inefficiencies, and support value-based models. 

“This model is built to accelerate access, improve outcomes and deliver smarter, more transparent drug commercialization at every step,” Thierer said.